News

DOD Awards Dynavax $22 Million for Plague Vaccine Clinical Trial
November 3, 2021 — The U.S. Department of Defense (DOD) awarded Dynavax Technologies Corporation with an agreement worth approximately $22 million over two and a half years, to execute a clinical trial combining the DOD’s recombinant plague (rF1V) vaccine with its own CpG 1018® adjuvant. Under the agreement, Dynavax will conduct a Phase II clinical trial in 2022. ... MORE

Key Federal Partners Gather to Plan, Act on Emerging CBRN Threats
October 12, 2021 — Efforts to prepare the U.S. military for a series of evolving threats to both the Warfighter and the nation at-large took center stage during the 2021 CBRN Defense Conference and Exhibition in Baltimore, Maryland from August 16-18... MORE

CBRND leadership speak on a panel at the 2021 CBRN Defense Conference

JPM CBRN Medical Provides Relief and Recovery in the Age of a Global Pandemic
October 4, 2021 — The JPM CBRN Medical team is dedicated to mission, warfighter, and Nation. Their work has been instrumental in bringing novel testing capability to the U.S., delivering critical at-home technology necessary to combat the global COVID-19 pandemic. In spearheading the mission of supporting the warfighter, the team indirectly boosted the local economy and remain ready for the next threat, whether intentional or naturally-occurring... MORE

Two uniformed service members are in a tent. One wears PPE and a faceshield, while they use a nasal swab to collect a COVID-19 sample from the other Service member in uniform.

JPM CBRN Medical Provides Relief and Recovery in the Age of a Global Pandemic
September 8, 2021 — What do global pandemic relief efforts, the U.S. Army, and a local Maryland economy have in common? The answer is fearless innovation, the right people in the right place at the right time, and an Australian-based biotech and diagnostic solutions company named Ellume. ... MORE

Aerial photo of Ellume's new Fredrick, MD diagnostics manufacturing facility.

DOD Awards $64.6 Million Contract to SiO2 Medical Products to Increase Domestic Production Capacity of Pharmaceutical Vials
July 29, 2021 — IMMEDIATE RELEASE - On July 26, 2021, the Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a $64.6 million contract modification to SiO2 Medical Products to increase domestic production of pharmaceutical vials made of hybrid, glass-equivalent materials... MORE

Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics.

Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment
June 9, 2021 — The Biden Administration today announced that the U.S. government will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for COVID-19 from Merck, pending emergency use authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA).Molnupiravir (MK-4482) is designed to... MORE

American flags against a blue sky background

Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
May 26, 2021 — On May 20, 2021, Deputy Secretary of Defense Kathleen Hicks and Deputy Secretary of Health and Human Services (HHS) Andrea Palm signed a memorandum of understanding (MOU) to continue the agencies’ partnership in defeating COVID-19 and preparing for future public health emergencies.The MOU establishes the framework under which the Department of... MORE

Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021 — Excerpt from NCT Magazine's Interview with Dr. Kevin Wingerd, Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)... MORE

The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
May 25, 2021 — In early 2020, the world as we knew it began to change. Lockdowns, mask mandates, and travel bans became the new normal as the world fought to slow the spread of the coronavirus (COVID-19).Priorities began to shift, and the development of safe and efficacious vaccines and therapeutics for COVID-19, along with the diagnostic capability needed to... MORE

DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
May 24, 2021 — As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand the production of the low dead-space (LDS) safety syringes and needles. Government funding allocated was $27.3 million.LDS... MORE

COVID-19 vaccine rollout ongoing in U.S. Army Central footprint

News Search

News Archive - Search by Year and Month

April 2024 (1)
March 2024 (3)
February 2024 (3)
January 2024 (2)
December 2023 (2)
November 2023 (2)
October 2023 (5)
September 2023 (6)
August 2023 (8)
July 2023 (2)
June 2023 (2)
May 2023 (3)
April 2023 (2)
March 2023 (1)
February 2023 (1)
January 2023 (1)
December 2022 (4)
November 2022 (1)
October 2022 (3)
September 2022 (5)
August 2022 (3)
July 2022 (3)
June 2022 (1)
May 2022 (1)
March 2022 (2)
February 2022 (2)
January 2022 (5)
December 2021 (1)
November 2021 (6)
October 2021 (2)
September 2021 (1)
July 2021 (1)
June 2021 (1)
May 2021 (8)
April 2021 (6)
March 2021 (2)
February 2021 (5)
January 2021 (4)
December 2020 (3)
November 2020 (1)
August 2020 (1)
July 2020 (3)
May 2020 (1)
April 2020 (1)
March 2020 (4)
February 2020 (1)
December 2019 (2)
November 2019 (2)
October 2019 (2)
September 2019 (2)
March 2019 (1)
January 2019 (2)
December 2018 (1)
October 2018 (1)
July 2018 (1)
April 2018 (1)
February 2018 (1)
December 2017 (1)
November 2017 (2)
September 2017 (1)
June 2017 (2)
January 2017 (3)
December 2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.